Site Editor

Leo I. Gordon, MD, FACP


Predicting Survival Outcomes With PET Radiomics in Diffuse Large B-Cell Lymphoma

By: Julia Fiederlein
Posted: Tuesday, May 31, 2022

Luca Ceriani, PhD, of Ente Ospedaliero Cantonale, Bellinzona, Switzerland, and colleagues investigated the prognostic value of PET radiomics in patients with diffuse large B-cell lymphoma who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). The post hoc analysis of the SAKK 38/07 trial, which was published in Hematological Oncology, provided proof of principle for the application of radiomic models in this clinical setting.

“The radiomics score allowed [for the] risk classification of patients with significantly different progression-free, cause-specific, and overall survival in both cohorts [and showed] better predictive accuracy [with] respect to clinical international indices,” the investigators remarked. “PET-derived radiomics may improve the prediction of outcomes in patients with diffuse large B-cell lymphoma.”

A total of 107 radiomics features were extracted from the baseline PET scans of 133 patients who were treated with R-CHOP every 14 days in the SAKK 38/07 trial. A least absolute shrinkage and selection operator Cox regression analysis was performed to assess the impact of the international prognostic indices; main clinical parameters; standard PET metrics; and 52 radiomics uncorrelated features on progression-free, cause-specific, and overall survival outcomes. A linear combination of the resulting parameters generated the prognostic radiomics score. The efficacy of the radiomics score was validated in an independent cohort of 107 patients who received R-CHOP every 21 days.

The investigators identified four radiomics features that seemed to predict progression-free survival outcomes in the SAKK 38/07 trial. In both the testing (P < .001) and validation (P < .001) sets, the derived radiomics score demonstrated a significant capability to predict progression-free survival outcomes. The radiomics score also seemed to be significantly associated with cause-specific and overall survival in the testing (P < .001 and P < .001, respectively) and validation (P < .0001 and P = .004, respectively) sets.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.